[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643087":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":33,"responsibleParty":49,"collaborators":11,"id":51,"slug":11,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":11,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":77,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"University Medical Center Groningen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"WGA-800CW","EXPERIMENTAL",null,[13],"Drug: WGA-800CW",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","Lectin-based fluorescent tracer",[9],[20],{"name":21,"affiliation":5,"role":22},"W.B. Nagengast, Dr, MD","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Jonathan Shaheen, PharmD","CONTACT","+31621927538","j.shaheen@umcg.nl",{"name":30,"role":26,"phone":31,"phoneExt":11,"email":32},"Chair\u002FHead of the Department of Gastroenterology and Hepatolog","+31503616161","w.b.nagengast@umcg.nl",[34],{"facility":5,"status":11,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Groningen","Provincie Groningen","9713 GZ","Netherlands",{"type":40,"coordinates":41},"Point",[42,43],6.56667,53.21917,{"lat":43,"lon":42},[46,48],{"name":47,"role":26,"phone":31,"phoneExt":11,"email":32},"Wouter B Nagengast, PharmD, MD, PhD",{"name":47,"role":22,"phone":11,"phoneExt":11,"email":11},{"type":50,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100643087",false,"NCT07643727","Development of Fluorescent Lectin Tracers With Dedicated Technology for in Vivo Detection of Esophageal Dysplasia in Barrett Patients","Glycan Near-Infrared Imaging Using Fluorescently Labeled Wheat Germ Agglutinin (WGA): Evaluation of Safety and Feasibility in a Prospective Pilot Study","GRAIN","Inclusion Criteria:\n\n* Patients with confirmed Barrett's esophagus, esophageal dysplasia, or superficial esophageal ade-nocarcinoma.\n* Patients scheduled for gastroscopy procedure within the UMCG.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Known allergy to wheat.\n* Celiac disease.\n* Dermatitis herpetiformis.\n* Pregnancy or breastfeeding.","ALL","18 Years",{"count":61,"type":62},49,"ESTIMATED","INTERVENTIONAL",[65],"PHASE1","The goal of this clinical trial is to evaluate the feasibility of WGA-800CW with dedicated imaging systems for detection of invisible esophageal dysplasia in patients with Barrett's esophagus.\n\nThe main questions it aims to answer are:\n\n* What is the optimal dose of WGA-800CW that maximizes the tumor-to-background ratio and enables clear visualization of the tumor?\n* Can fluorescence endoscopy with WGA-800CW in combination with qFME detect dysplastic esophageal lesions?\n\nIn this non-randomized, non-blinded, prospective, feasibility intervention study, 49 participants with Barrett's esophagus will be included. Patients will undergo the combined procedure (qFME and\u002For OCT-NIRF and HD-WLE). WGA-800CW will be topically administered via a spray catheter during gastroscopy procedures and fluorescent signal will be assessed with qFME and\u002For OCT-NIRF.",[68,69],"Barrett's Esophagus With or Without Dysplasia","Barrett Esophagus Adenocarcinoma",[71,72,73,74,75,76],"Glycan","Oncology","Fluorescent tracers","qFME","First-in-human","Lectin","NOT_YET_RECRUITING","2026-06-08",{"date":80,"type":81},"2026-06-11","ACTUAL",{"date":83,"type":62},"2026-06-01",{"date":85,"type":62},"2028-10-31",{"name":5,"class":6},1]